-
T-DXd Improves All Outcomes in Post-Hoc Look of DESTINY-Breast06 in HR+, HER2-Low/-Ultralow Metastatic Breast Cancer
15 May 2025 21:24 GMT
… (Xeloda) or taxane (nab-paclitaxel [Abraxane] or paclitaxel) as second- or … -low or HER2-ultralow metastatic breast cancer, according to additional data from … identify patients with HER2-ultralow breast cancer.
Additional Trial Objectives, Findings, and …
-
Sacituzumab Govitecan-hziy Plus Pembrolizumab Improves PFS in Patients With Metastatic Triple-Negative Breast Cancer
24 Apr 2025 17:33 GMT
… -Myers Squibb], paclitaxel [Abraxane; Abraxis BioScience, LLC], … metastatic triple-negative breast cancer (ASCENT-04). … Navigating triple-negative breast cancer treatment with sacituzumab … navigating-triple-negative-breast-cancer-treatment-with-sacituzumab …
-
Sacituzumab Govitecan/Pembrolizumab Show Promise as SOC in 1st Line PD-L1+ TNBC
31 May 2025 14:40 GMT
… , advanced or metastatic triple-negative breast cancer (TNBC), based on results from … /m2 of nab-paclitaxel (Abraxane) on days 1, 8, and … -L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the …
-
Anthracycline-Sparing Strategies Help Refine HER2+ Breast Cancer Management
17 Apr 2025 12:56 GMT
… management of HER2-positive breast cancer; highlighted the enduring … treatment for advanced HER2-positive breast cancer?
[When] talking [about] … for metastatic HER2-positive breast cancer, we have to … docetaxel, and nab-paclitaxel [Abraxane] was also an option …
-
Dr Tarantino on Frontline Treatment Considerations in Metastatic HER2+ Breast Cancer
16 Apr 2025 20:34 GMT
… treatment of metastatic HER2-positive breast cancer and how evolving data have … that paclitaxel and nab-paclitaxel (Abraxane) may be substituted for docetaxel …
-
Meitheal Pharma launches generic paclitaxel formulation in US via exclusive commercial licensing agreement with Hong Kong King─Friend
31 May 2025 08:44 GMT
… a generic form of Abraxane 2, in the United … the treatment of metastatic breast cancer, metastatic adenocarcinoma of … the treatment of metastatic breast cancer, and additional types … cancer, including metastatic breast cancer and metastatic adenocarcinoma of …
-
T-DXd Wins EU Approval for HR+, HER2-Low or -Ultralow Metastatic Breast Cancer After Endocrine Therapy
04 Apr 2025 17:59 GMT
… receptor–positive metastatic breast cancers that express HER2,” … capecitabine, nab-paclitaxel (Abraxane), or paclitaxel.
PFS … of patients with metastatic breast cancer,” Dave Fredrickson, … HER2-ultralow metastatic breast cancer following disease progression …
-
Dr Heldermon on a Phase 1/2 Trial Design of Epidiferphane Plus a Taxane in Breast Cancer
12 Mar 2025 20:54 GMT
… professor of medicine and breast cancer specialist, Division of … in patients with breast cancer.
Although the breast cancer treatment paradigm … m2), or nab-paclitaxel (Abraxane) weekly or every 3 … clinical diagnosis of metastatic breast cancer. Patients on the …
-
Immunotherapies Spark Excitement in Triple-Negative Breast Cancer Treatment
08 Mar 2025 13:21 GMT
… breast cancer, and Komen Distinguished Chair in Clinical Breast Cancer … of cisplatin/Abraxane/pembrolizumab followed … breast cancer. Presented at: 2024 San Antonio Breast Cancer … breast cancer (TNBC). Presented at: 2024 San Antonio Breast Cancer …
-
T-DXd Receives Positive CHMP Opinion for HER2-Low or HER2-Ultralow Metastatic Breast Cancer
28 Feb 2025 19:58 GMT
… low or HER2-ultralow metastatic breast cancer following endocrine therapy,” Ken … comprising capecitabine, nab-paclitaxel (Abraxane), or paclitaxel.
Key stratification … or HER2-ultralow metastatic breast cancer following disease progression after …
About
© 1995-2025